Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2001 December;26(4) > Minerva Endocrinologica 2001 December;26(4):239-46

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ENDOCRINOLOGICA

A Journal on Endocrine System Diseases


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118


eTOC

 

  NEW DIAGNOSTIC AND THERAPEUTIC STRATEGIES: SOMATOSTATIN ANALOGS. Part II


Minerva Endocrinologica 2001 December;26(4):239-46

Copyright © 2001 EDIZIONI MINERVA MEDICA

language: Italian

New therapeutic prospects in microcytoma

Lorusso V., Crucitta E.


PDF  


The therapeutic efforts of the past thirty years have been directed at improving the scant prognosis of patients suffering from microcytoma (SCLC) using a combination of chemotherapy and radiotherapy. Studies have shown that the longest survival rates are achieved when radiotherapy is administered concomitantly with chemotherapy. No clear correlation has been identified between the 3-year disease-free survival rate and the type of chemotherapy used. The standard treatment for patients suffering from SCLC is currently polychemotherapy using protocols with cisplatin, with or without radiotherapy. Among the new protocols that have been proposed, an increase in dose intensity, weekly therapy and alternating chemotherapy appear to give the most promising results, even if no studies have so far actually demonstrated their ability to improve results.

top of page

Publication History

Cite this article as

Corresponding author e-mail